Hypercholesterolemia, low density lipoprotein receptor and proprotein convertase subtilisin/kexin-type 9

Journal of Biomedical Research

Volumn 29, Issue 5, 2015, Pages 356-361

  Gu, Hong Mei ^a   Zhang, Da Wei ^a  

^a UNIVERSITY OF ALBERTA   (Canada)

Author keywords

Atherosclerosis; Hypercholesterolemia; Low density lipoprotein receptor; Proprotein convertase subtilisin kexin type 9; Statin

Indexed keywords

APOLIPOPROTEIN B; APOLIPOPROTEIN E; EPIDERMAL GROWTH FACTOR; KEXIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN RECEPTOR; PROPROTEIN CONVERTASE SUBTILISIN KEXIN TYPE 9; STEROL REGULATORY ELEMENT BINDING PROTEIN 2; SUBTILISIN; UNCLASSIFIED DRUG;

CARDIOVASCULAR DISEASE; CHOLESTEROL BLOOD LEVEL; CONFORMATIONAL TRANSITION; HUMAN; HYPERCHOLESTEROLEMIA; LIGAND BINDING; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PROCESSING; REVIEW;

EID: 84944402980     PISSN: 16748301     EISSN: None     Source Type: Journal    
DOI: 10.7555/JBR.29.20150067     Document Type: Review

References (62)

1. Libby P. Inflammation in atherosclerosis[J]. Nature, 2002,420(6917):868-874.
2. Brown MS, Goldstein JL. Biomedicine. Lowering LDL-not only how low, but how long?[J]. Science, 2006,311(5768): 1721-1723.
3. Goldstein JL, Brown MS. The LDL receptor[J]. Arterioscler Thromb Vasc Biol, 2009,29(4):431-438.
4. Tiwari RL, Singh V, Barthwal MK. Macrophages: an elusive yet emerging therapeutic target of atherosclerosis[J]. Med Res Rev, 2008,28(4):483-544.
5. Platt N, Gordon S. Is the class A macrophage scavenger receptor (SR-A) multifunctional?-The mouse's tale[J]. J Clin Invest, 2001,108(5):649-654.
6. Russell DW, Brown MS, Goldstein JL. Different combinations of cysteine-rich repeats mediate binding of low density lipoprotein receptor to two different proteins[J]. J Biol Chem, 1989,264(36):21682-21688.
7. Jeon H, Meng W, Takagi J, et al. Implications for familial hypercholesterolemia from the structure of the LDL receptor YWTD-EGF domain pair[J]. Nat Struct Biol, 2001, 8(6):499-504.
8. Davis CG, Goldstein JL, Sudhof TC, et al. Acid-dependent ligand dissociation and recycling of LDL receptor mediated by growth factor homology region[J]. Nature, 1987,326(6115):760-765.
9. Beglova N, Jeon H, Fisher C, et al. Cooperation between fixed and low pH-inducible interfaces controls lipoprotein release by the LDL receptor[J]. Mol Cell, 2004,16(2):281-292.
10. Rudenko G, Henry L, Henderson K, et al. Structure of the LDL receptor extracellular domain at endosomal pH[J]. Science, 2002,298(5602):2353-2358.
11. Ishibashi S, Brown MS, Goldstein JL, et al. Hypercholesterolemia in low density lipoprotein receptor knockout mice and its reversal by adenovirus-mediated gene delivery[J]. J Clin Invest, 1993,92(2):883-893.
12. Schreyer SA, Vick C, Lystig TC, et al. LDL receptor but not apolipoprotein E deficiency increases diet-induced obesity and diabetes in mice[J]. Am J Physiol Endocrinol Metab, 2002,282(1):E207-E214.
13. Merat S, Casanada F, Sutphin M, et al. Western-type diets induce insulin resistance and hyperinsulinemia in LDL receptor-deficient mice but do not increase aortic atherosclerosis compared with normoinsulinemic mice in which similar plasma cholesterol levels are achieved by a fructose-rich diet[J]. Arterioscler Thromb Vasc Biol, 1999,19(5): 1223-1230.
14. Bonfleur ML, Vanzela EC, Ribeiro RA, et al. Primary hypercholesterolaemia impairs glucose homeostasis and insulin secretion in low-density lipoprotein receptor knockout mice independently of high-fat diet and obesity[J]. Biochim Biophys Acta, 2010,1801(2):183-190.
15. Lagace TA, Curtis DE, Garuti R, et al. Secreted PCSK9 decreases the number of LDL receptors in hepatocytes and in livers of parabiotic mice[J]. J Clin Invest, 2006,116(11): 2995-3005.
16. Zhang DW, Lagace TA, Garuti R, et al. Binding of proprotein convertase subtilisin/kexin type 9 to epidermal growthfactor-likerepeatAoflowdensitylipoproteinreceptor decreases receptor recycling and increases degradation[J]. J Biol Chem, 2007,282(25):18602-18612.
17. Zelcer N, Hong C, Boyadjian R, et al. LXR regulates cholesterol uptake through Idol-dependent ubiquitination of the LDL receptor[J]. Science, 2009,325(5936):100-104.
18. Abifadel M, Varret M, Rabes JP, et al. Mutations in PCSK9 cause autosomal dominant hypercholesterolemia[J]. Nat Genet, 2003,34(2):154-156.
19. Leren TP. Mutations in the PCSK9 gene in Norwegian subjects with autosomal dominant hypercholesterolemia[J]. Clin Genet, 2004,65(5):419-422.
20. Abifadel M, Rabes JP, Devillers M, et al. Mutations and polymorphisms in the proprotein convertase subtilisin kexin 9 (PCSK9) gene in cholesterol metabolism and disease[J]. Hum Mutat, 2009,30(4):520-529.
21. Cohen JC, Boerwinkle E, Mosley TH, Jr., et al. Sequence variations in PCSK9, low LDL, and protection against coronary heart disease[J]. N Engl J Med, 2006,354(12):1264-1272.
22. Seidah NG, Khatib AM, Prat A. The proprotein convertases and their implication in sterol and/or lipid metabolism[J]. Biol Chem, 2006,387(7):871-877.
23. Abifadel M, Rabes JP, Jambart S, et al. The molecular basis of familial hypercholesterolemia in Lebanon: spectrum of LDLR mutations and role of PCSK9 as a modifier gene[J]. Hum Mutat, 2009,30(7):E682-E691.
24. Sabatine MS, Giugliano RP, Wiviott SD, et al. Efficacy and safety of evolocumab in reducing lipids and cardiovascular events[J]. N Engl J Med, 2015,372(16):1500-1509.
25. Cannon CP, Cariou B, Blom D, et al. Efficacy and safety of alirocumab in high cardiovascular risk patients with inadequately controlled hypercholesterolaemia on maximally tolerated doses of statins: the ODYSSEY COMBO II randomized controlled trial[J]. Eur Heart J, 2015,36(19):1186-1194.
26. Robinson JG, Farnier M, Krempf M, et al. Efficacy and safety of alirocumab in reducing lipids and cardiovascular events[J]. N Engl J Med, 2015,372(16):1489-1499.
27. Seidah NG, Mayer G, Zaid A, et al. The activation and physiological functions of the proprotein convertases[J]. Int J Biochem Cell Biol, 2008,40(6-7):1111-1125.
28. Benjannet S, Rhainds D, Essalmani R, et al. NARC-1/PCSK9 and its natural mutants: zymogen cleavage and effects on the low density lipoprotein (LDL) receptor and LDL cholesterol[J]. J Biol Chem, 2004,279(47):48865-48875.
29. Gustafsen C, Kjolby M, Nyegaard M, et al. The Hypercholesterolemia-Risk Gene SORT1 Facilitates PCSK9 Secretion[J]. Cell Metab, 2014,19(2):310-318.
30. SeidahNG, BenjannetS,WickhamL, etal.Thesecretoryproprotein convertase neural apoptosis-regulated convertase 1 (NARC-1): liver regeneration and neuronal differentiation[J]. Proc Natl Acad Sci U S A, 2003,100(3):928-933.
31. Horton JD, Shah NA, Warrington JA, et al. Combined analysis of oligonucleotide microarray data from transgenic and knockout mice identifies direct SREBP target genes[J]. Proc Natl Acad Sci U S A, 2003,100(21):12027-12032.
32. Mayne J, Dewpura T, Raymond A, et al. Plasma PCSK9 levels are significantly modified by statins and fibrates in humans[J]. Lipids Health Dis 2008,7(22).
33. Lambert G, Ancellin N, Charlton F, et al. Plasma PCSK9 concentrations correlate with LDL and total cholesterol in diabetic patients and are decreased by fenofibrate treatment[J]. Clin Chem, 2008,54(6):1038-1045.
34. Alborn WE, Cao G, Careskey HE, et al. Serum proprotein convertase subtilisin kexin type 9 is correlated directly with serum LDL cholesterol[J]. Clin Chem, 2007,53(10):1814-1819.
35. Maxwell KN, Breslow JL. Adenoviral-mediated expression of Pcsk9 in mice results in a low-density lipoprotein receptor knockout phenotype[J]. Proc Natl Acad Sci U S A, 2004,101(18):7100-7105.
36. Park SW, Moon YA, Horton JD. Post-transcriptional regulation of low density lipoprotein receptor protein by proprotein convertase subtilisin/kexin type 9a in mouse liver[J]. J Biol Chem, 2004,279(48):50630-50638.
37. Rashid S, Curtis DE, Garuti R, et al. Decreased plasma cholesterol and hypersensitivity to statins in mice lacking Pcsk9[J]. Proc Natl Acad Sci U S A, 2005,102(15):5374-5379.
38. Frank-Kamenetsky M, Grefhorst A, Anderson NN, et al. Therapeutic RNAi targeting PCSK9 acutely lowers plasma cholesterol in rodents and LDL cholesterol in nonhuman primates[J]. Proc Natl Acad Sci U S A, 2008,105(33): 11915-11920.
39. Cunningham D, Danley DE, Geoghegan KF, et al. Structural and biophysical studies of PCSK9 and its mutants linked to familial hypercholesterolemia[J]. Nat Struct Mol Biol, 2007,14(5):413-419.
40. McNutt MC, Kwon HJ, Chen C, et al. Antagonism of secreted PCSK9 increases low-density lipoprotein receptor expression in HEPG2 cells[J]. J Biol Chem, 2009, 284(16):10561-10570.
41. Zhang DW, Garuti R, Tang WJ, et al. Structural requirements for PCSK9-mediated degradation of the low-density lipoprotein receptor[J]. Proc Natl Acad Sci U S A, 2008, 105(35):13045-13050.
42. Gu HM, Adijiang A, Mah M, et al. Characterization of the role of EGF-A of low-density lipoprotein receptor in PCSK9 binding[J]. J Lipid Res, 2013,54(12):3345-3357.
43. Lalanne F, Lambert G, Amar MJ, et al. Wild-type PCSK9 inhibits LDL clearance but does not affect apoB-containing lipoprotein production in mouse and cultured cells[J]. J Lipid Res, 2005,46(6):1312-1319.
44. Wang Y, Huang Y, Hobbs HH, et al. Molecular characterization of proprotein convertase subtilisin/kexin type 9-mediated degradation of the LDLR[J]. J Lipid Res, 2012,53(9):1932-1943.
45. Fasano T, Sun XM, Patel DD, et al. Degradation of LDLR protein mediated by 'gain of function' PCSK9 mutants in normal and ARH cells[J]. Atherosclerosis, 2009,203(1):166-171.
46. Maxwell KN, Fisher EA, Breslow JL. Overexpression of PCSK9 accelerates the degradation of the LDLR in a post-endoplasmic reticulum compartment[J]. Proc Natl Acad Sci U S A, 2005,102(6):2069-2074.
47. Poirier S, Mayer G, Poupon V, et al. Dissection of the endogenous cellular pathways of PCSK9-induced LDLR degradation: Evidence for an intracellular route[J]. J Biol Chem, 2009,284(42):28856-28864.
48. Grefhorst A, McNutt MC, Lagace TA, et al. Plasma PCSK9 preferentially reduces liver LDL receptors in mice[J]. J Lipid Res, 2008,49(6):1303-1311.
49. Luo Y, Warren L, Xia D, et al. Function and distribution of circulating human PCSK9 expressed extrahepatically in transgenic mice[J]. J Lipid Res, 2009,50(8):1581-1588.
50. Cariou B, Benoit I, Le May C. Preserved adrenal function in fully PCSK9-deficient subject[J]. Int J Cardiol, 2014,176(2):499-500.
51. Benjannet S, Rhainds D, Hamelin J, et al. The proprotein convertase (PC) PCSK9 is inactivated by furin and/or PC5/6A: functional consequences of natural mutations and post-translational modifications[J]. J Biol Chem, 2006,281(41):30561-30572.
52. Maxwell KN, Breslow JL. Proprotein convertase subtilisin kexin 9: the third locus implicated in autosomal dominant hypercholesterolemia[J]. Curr Opin Lipidol, 2005, 16(2):167-172.
53. Mayer G, Poirier S, Seidah NG. Annexin A2 is a C-terminal PCSK9 binding protein that regulates endogenous LDL receptor levels[J]. J Biol Chem, 2008,283(46): 31791-31780.
54. Nguyen MA, Kosenko T, Lagace TA. Internalized PCSK9 dissociates from recycling LDL receptors in PCSK9-resistant SV-589 fibroblasts[J]. J Lipid Res, 2014,55(2):266-275.
55. McNutt MC, Lagace TA, Horton JD. Catalytic activity is not required for secreted PCSK9 to reduce low density lipoprotein receptors in HepG2 cells[J]. J Biol Chem, 2007,282(29):20799-20803.
56. Surdo PL, Bottomley MJ, Calzetta A, et al. Mechanistic implications for LDL receptor degradation from the PCSK9/LDLR structure at neutral pH[J]. EMBO Rep, 2011,12(12):1300-1305.
57. Tveten K, Holla OL, Cameron J, et al. Interaction between the ligand-binding domain of the LDL receptor and the Cterminal domain of PCSK9 is required for PCSK9 to remain bound to the LDL receptor during endosomal acidification[J]. Hum Mol Genet, 2012,21(6):1402-1409.
58. Holla OL, Cameron J, Tveten K, et al. Role of the C-terminal domain of PCSK9 in degradation of the LDL receptors[J]. J Lipid Res, 2011,52(10):1787-1794.
59. Yamamoto T, Lu C, Ryan RO. A two-step binding model of PCSK9 interaction with the low density lipoprotein receptor[J]. J Biol Chem, 2011,286(7):5464-5470.
60. Stein EA, Raal FJ. Targeting LDL: is lower better and is it safe?[J]. Best Pract Res Clin Endocrinol Metab, 2014,28(3): 309-324.
61. Sattar N, Preiss D, Murray HM, et al. Statins and risk of incident diabetes: a collaborative meta-analysis of randomised statin trials[J]. Lancet, 2010,375(9716):735-742.
62. Goldstein JL, Hobbs HH, Brown MS. Familial Hypercholesterol[M]. In: Scriver CR. The Metabolic & Molecular Bases of Inherited Disease, eighth edition. New York: McGraw-Hill, 2001:2863-2913.